Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put GlaxoSmithKline PLC (GSK Quick QuoteGSK - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, GlaxoSmithKline’s has a trailing twelve months PE ratio of 15.51, as you can see in the chart below:




This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 20.37. If we focus on the long-term PE trend, GlaxoSmithKline’ current PE level puts it above its midpoint over the past five years.



Further, the stock’s PE also compares favorably with the Zacks classified Medical sector’s trailing twelve months PE ratio, which stands at 19.62. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.



We should also point out that GlaxoSmithKline has a forward PE ratio (price relative to this year’s earnings) of 15.44, so it is fair to say that a slightly more value-oriented path may be ahead for the stock in the near term too.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, GlaxoSmithKline has a P/S ratio of 2.81. This is lower than the S&P 500 average, which comes in at 3.15 right now.



If anything, this suggests some level of undervalued trading—at least compared to historical norms.

Broad Value Outlook

In aggregate, GlaxoSmithKline currently has a Zacks Value Style Score of ‘B’, putting it into the top 40% of all stocks we cover from this look. This makes GSK a solid choice for value investors, and some of its other key metrics make this pretty clear too.

For example, the P/CF ratio (another great indicator of value) comes in at 12.70, which is far better than the industry average of 18.82. Clearly, GSK is a solid choice on the value front from multiple angles.

What About the Stock Overall?

Though GlaxoSmithKline might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of ‘B’ and a Momentum score of ‘C’. This gives BAYRY a Zacks VGM score—or its overarching fundamental grade—of ‘B’. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been mixed at best. The current quarter has seen no upward estimate revision in the past sixty days compared to one downward, while the current year estimate has seen four upward and one downward revisions in the same time frame.

As a result, the current quarter consensus estimate has moved down by 2.8% in the past two months, while the current year estimate has inched higher by 3.3%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

GlaxoSmithKline PLC Price and Consensus

This somewhat mixed trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term.

Bottom Line

GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Furthermore, a good industry rank (among the Top 27%) instills investor confidence. In fact, over the past six months, the Zacks categorized Large Cap Pharmaceutical industry has clearly outperformed the broader market, as you can see below:



However, the Zacks #3 indicates that while the stock’s growth story is intact over the medium term, analysts have some apprehensions about the stock in the immediate future. So, value investors might want to wait for analyst sentiment and estimates to turn favorable in this name first, but once that happen, this stock could be a compelling pick

3 Top Picks to Ride the Hottest Tech Trend

Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...

Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>